Curis Inc. (NASDAQ:CRIS) went down by -5.45% from its latest closing price compared to the recent 1-year high of $13.44. The company’s stock price has collected -4.39% of loss in the last five trading sessions. Press Release reported on 04/19/21 that Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Is It Worth Investing in Curis Inc. (NASDAQ :CRIS) Right Now?
Plus, the 36-month beta value for CRIS is at 2.97. Opinions of the stock are interesting as 5 analysts out of 5 who provided ratings for Curis Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $17.20, which is $6.97 above the current price. CRIS currently public float of 63.00M and currently shorts hold a 18.19% ratio of that float. Today, the average trading volume of CRIS was 1.88M shares.
CRIS’s Market Performance
CRIS stocks went down by -4.39% for the week, with a monthly drop of -13.67% and a quarterly performance of -1.06%, while its annual performance rate touched 1103.53%. The volatility ratio for the week stands at 6.16% while the volatility levels for the past 30 days are set at 7.31% for Curis Inc.. The simple moving average for the period of the last 20 days is -8.03% for CRIS stocks with a simple moving average of 81.44% for the last 200 days.
Analysts’ Opinion of CRIS
Many brokerage firms have already submitted their reports for CRIS stocks, with B. Riley Securities repeating the rating for CRIS by listing it as a “Buy.” The predicted price for CRIS in the upcoming period, according to B. Riley Securities is $19 based on the research report published on March 25th of the current year 2021.
Laidlaw, on the other hand, stated in their research note that they expect to see CRIS reach a price target of $5. The rating they have provided for CRIS stocks is “Buy” according to the report published on July 29th, 2020.
Cantor Fitzgerald gave a rating of “Overweight” to CRIS, setting the target price at $4 in the report published on July 17th of the previous year.
CRIS Trading at -5.35% from the 50-Day Moving Average
After a stumble in the market that brought CRIS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.88% of loss for the given period.
Volatility was left at 7.31%, however, over the last 30 days, the volatility rate increased by 6.16%, as shares sank -17.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.39% lower at present.
During the last 5 trading sessions, CRIS fell by -4.39%, which changed the moving average for the period of 200-days by +766.95% in comparison to the 20-day moving average, which settled at $11.01. In addition, Curis Inc. saw 24.91% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at CRIS starting from Dentzer James E, who sale 3,094 shares at the price of $10.59 back on Jan 26. After this action, Dentzer James E now owns 67,268 shares of Curis Inc., valued at $32,758 using the latest closing price.
Dentzer James E, the President & CEO of Curis Inc., sale 2,283 shares at $10.96 during a trade that took place back on Jan 25, which means that Dentzer James E is holding 70,362 shares at $25,022 based on the most recent closing price.
Stock Fundamentals for CRIS
Current profitability levels for the company are sitting at:
- -229.79 for the present operating margin
- +93.74 for the gross margin
The net margin for Curis Inc. stands at -276.03. The total capital return value is set at -22.10, while invested capital returns managed to touch -26.84. Equity return is now at value -380.80, with -37.20 for asset returns.
Based on Curis Inc. (CRIS), the company’s capital structure generated 50.43 points at debt to equity in total, while total debt to capital is 33.52. Total debt to assets is 31.97, with long-term debt to equity ratio resting at 48.68. Finally, the long-term debt to capital ratio is 32.36.
When we switch over and look at the enterprise to sales, we see a ratio of 27.32, with the company’s debt to enterprise value settled at 0.22. The receivables turnover for the company is 3.45 and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.14.